Proposed Data Collections Submitted for Public Comment and Recommendations, 43138-43139 [E9-20578]
Download as PDF
jlentini on DSKJ8SOYB1PROD with NOTICES
43138
Federal Register / Vol. 74, No. 164 / Wednesday, August 26, 2009 / Notices
Journal of Cereal Science 47(2): 118–133,
2008.
37. Friedman, M., and C.E. Levin, ‘‘Review
of methods for the reduction of dietary
content and toxicity of acrylamide,’’ Journal
of Agricultural and Food Chemistry 56(15):
6113–40, 2008.
38. Foot, R.J., N.U. Haase, K. Grob, and P.
´
Gonde, ‘‘Acrylamide in fried and roasted
potato products: a review on progress in
mitigation,’’ Food Additives and
Contaminants 24(Suppl 1): 37–46, 2007.
39. Guenther, H., E. Anklam, T. Wenzl, and
R.H. Stadler, ‘‘Acrylamide in coffee: review
of progress in analysis, formation and level
reduction,’’ Food Additives and
Contaminants 24(Suppl 1): 60–70, 2007.
40. Halford, N.G., N. Muttucumaru, T.Y.
Curtis, and M.A. Parry, ‘‘Genetic and
agronomic approaches to decreasing
acrylamide precursors in crop plants,’’ Food
Additives and Contaminants 24(Suppl 1):
26–36, 2007.
41. Konings, E.J., P. Ashby, C.G. Hamlet,
and G.A. Thompson, ‘‘Acrylamide in cereal
and cereal products: a review on progress in
level reduction,’’ Food Additives and
Contaminants 24(Suppl 1): 47–59, 2007.
42. Morales, F., E. Capuano, and V.
Fogliano, ‘‘Mitigation strategies to reduce
acrylamide formation in fried potato
products,’’ Annals of the New York Academy
of Sciences 1126: 89–100, 2008.
43. Muttucumaru, N., J.S. Elmore, T.
Curtis, D.S. Mottram, M.A. Parry, and N.G.
Halford, ‘‘Reducing acrylamide precursors in
raw materials derived from wheat and
potato,’’ Journal of Agricultural and Food
Chemistry 56(15): 6167–72, 2008.
44. Stadler, R.H., ‘‘Acrylamide formation in
different foods and potential strategies for
reduction,’’ Advances in Experimental
Medicine and Biology 561: 157–169, 2005.
45. Stadler, R.H., and G. Scholz,
‘‘Acrylamide: an update on current
knowledge in analysis, levels in food,
mechanisms of formation, and potential
strategies of control,’’ Nutrition Reviews
62(12): 449–67, 2004.
46. Taeymans, D., A. Andersson, P. Ashby,
´
I. Blank, P. Gonde, P. van Eijck, V. Faivre,
S.P. Lalljie, H. Lingnert, M. Lindblom, R.
¨
Matissek, D. Muller, R.H. Stadler, A. Studer,
D. Silvani, D. Tallmadge, G. Thompson, T.
Whitmore, J. Wood, and D. Zyzak.
‘‘Acrylamide: update on selected research
activities conducted by the European food
and drink industry,’’ Journal of AOAC
International 88(1): 234–41, 2005.
47. Taeymans, D., J. Wood, P. Ashby, I.
´
Blank, A. Studer, R.H. Stadler, P. Gonde, P.
Van Eijck, S. Lalljie, H. Lingnert, M.
¨
Lindblom, R. Matissek, D. Muller, D.
Tallmadge, J. O’Brien, S. Thompson, D.
Silvani, and T. Whitmore, ‘‘A review of
acrylamide: an industry perspective on
research, analysis, formation, and control,’’
Critical Reviews in Food Science and
Nutrition 44(5): 323–47, 2004.
48. Zhang, Y., and Y. Zhang, ‘‘Formation
and reduction of acrylamide in Maillard
reaction: a review based on the current state
of knowledge,’’ Critical Reviews in Food
Science and Nutrition 47(5): 521–542, 2007.
49. Confederation of Food and Drink
Industries of the EU (CIAA), ‘‘The CIAA
VerDate Nov<24>2008
17:05 Aug 25, 2009
Jkt 217001
Acrylamide ‘Toolbox’, Revision 12,’’ 2009.
Accessed online at https://www.ciaa.be/
documents/brochures/
ac_toolbox_20090216.pdf.
50. CIAA, ‘‘A ‘Toolbox’ for the Reduction
of Acrylamide in Biscuits, Crackers &
Crispbreads,’’ 2007. Accessed online at
https://www.ciaa.be/documents/others/
biscuits-EN-final.pdf.
51. CIAA, ‘‘A ‘Toolbox’ for the Reduction
of Acrylamide in Bread Products,’’ 2007.
Accessed online at https://www.ciaa.be/
documents/others/bread-EN-final.pdf.
52. CIAA, ‘‘A ‘Toolbox’ for the Reduction
of Acrylamide in Breakfast Cereals,’’ 2007.
Accessed online at https://www.ciaa.be/
documents/others/cereals-EN-final.pdf.
53. CIAA, ‘‘A ‘Toolbox’ for the Reduction
of Acrylamide in Fried Potato Products
Potato Crisps,’’ 2007. Accessed online at
https://www.ciaa.be/documents/others/crispsEN-final.pdf.
54. CIAA, ‘‘A ‘Toolbox’ for the Reduction
of Acrylamide in Fried Potato Products/
French Fries,’’ 2007. Accessed online at
https://www.ciaa.be/documents/others/
french%20fries-EN-final.pdf.
55. Association of the Chocolate, Biscuits,
and Confectionery Industries of the EU
(CAOBISCO), CAOBISCO Review of
Acrylamide Mitigation in Biscuits, Crackers
and Crispbread, 2006. Accessed online at
https://www.caobisco.com/doc_uploads/
7254639e.pdf.
56. The HEATOX Project, ‘‘Guidelines to
Authorities and Consumer Organisations on
Home Cooking and Consumption,’’ 2006.
Accessed online at https://www.slv.se/upload/
heatox/documents/D59_guidelines_
to_authorities_and_consumer_organisations_
on_home_cooking_and_consumption.pdf.
57. The HEATOX Project, ‘‘Manual on
strategies to food industries, restaurants, etc.,
to minimize acrylamide formation,’’ 2006.
Accessed online at https://www.slv.se/upload/
heatox/documents/D60_manual_
on_strategies_to_food_industries_
restaurants_etc_to_minimise_acrylamide_
formation.pdf.
58. Joint FAO/WHO Food Standards
Programme Codex Committee on
Contaminants in Foods (CCCF), ‘‘Draft Code
of Practice for the Reduction of Acrylamide
in Foods (N06–2006),’’ In: Report of the 3rd
Session of the CCCF, Rotterdam, The
Netherlands, March 23–27 2009, ALINORM
09/32/41, 2009, Appendix IV. Accessed
online at https://www.codexalimentarius.net/
download/report/722/al32_41e.pdf.
59. European Commission Joint Research
Centre—Institute for Reference Materials and
Measurements, ‘‘Monitoring database on
acrylamide levels in food,’’ 2006. Accessed
online at https://irmm.jrc.ec.europa.eu/html/
activities/acrylamide/database.htm.
60. European Food Safety Authority
(EFSA), ‘‘Call for occurrence data on
acrylamide levels in food,’’ 2007. Accessed
online at https://www.efsa.europa.eu/EFSA/
efsa_locale-1178620753812_
1178656289168.htm.
61. The Commission of the European
Communities, ‘‘Commission
Recommendation of 3 May 2007 on the
monitoring of acrylamide levels in food
(2007/331/EC),’’ Official Journal of the
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
European Union, 12/5/2007, L 123/33–40.
Accessed online at https://eur-lex.europa.eu/
LexUriServ/site/en/oj/2007/l_123/
l_12320070512en00330040.pdf.
¨
62. Bundesamt fur Verbraucherschutz und
Lebensmittelsicherheit (BVL), ‘‘Concept of
minimising acrylamide contents in
foodstuffs,’’ 2005. Accessed online at https://
www.bvl.bund.de/cln_007/nn_521138/EN/
01_Food/04_Acrylamid_en/acrylamid_
EN_node.html_nnn=true.
63. Bonneck, S., ‘‘Acrylamide Risk
Governance in Germany,’’ In O. Renn and
K.D. Walker, Eds., Global Risk Governance,
2008. Accessed online at https://www.irgc.org/
IMG/pdf/Chapter_11_Acrylamides_final.pdf.
64. Health Canada, ‘‘Health Canada’s
Acrylamide Monitoring Program,’’ 2009.
Accessed online at https://www.hc-sc.gc.ca/
fn-an/securit/chem-chim/food-aliment/
acrylamide/monitoring-prog-surveillanceeng.php.
65. Office of the Attorney General, State of
California, News release: ‘‘Atty. Gen. Brown
Settles Potato Chip Lawsuit With Heinz,
Frito-Lay & Kettle Foods,’’ August 1, 2008.
Accessed online at https://ag.ca.gov/
newsalerts/release.php?id=1595&.
Dated: August 17, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–20495 Filed 8–25–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–09–0789]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 or send
comments to Maryam I. Daneshvar, CDC
Acting Reports Clearance Officer, 1600
Clifton Road, MS–D74, Atlanta, GA
30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
E:\FR\FM\26AUN1.SGM
26AUN1
43139
Federal Register / Vol. 74, No. 164 / Wednesday, August 26, 2009 / Notices
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Program Effectiveness Evaluation of
Workplace Intervention for Intimate
Partner Violence (IPV)—[OMB# 0920–
0789] [expiration date 12/31/09]—
Extension—National Center for Injury
Prevention and Control (NCIPC),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Intimate partner violence (IPV) affects
a substantial number of Americans, and
there has recently been increasing
recognition of the impact it has on the
workplace. In addition to direct impacts
(batterers often stalk or even attack IPV
victims at their place of work), IPV has
indirect impacts on the workplace
environment through lost productivity
due to medical leave, absenteeism, and
fear and distraction on the part of
victims and coworkers. The Centers for
Disease Control and Prevention (CDC)
contracted with RTI International (RTI)
to evaluate an ongoing workplace IPV
prevention program being implemented
at a national corporation. The purpose
of the proposed evaluation is to
document in detail the workplace IPV
prevention activities delivered by the
company, to determine the impact of
these activities on short-term and longterm outcomes, and to determine the
cost-effectiveness of the program. All
managers at the corporate office of the
corporation have been screened to
assess training experiences. More indepth surveys were conducted with
managers who had not completed the
corporation’s IPV training.
Approximately 200 managers have been
surveyed at baseline, and 6 months
later. Manager surveys focus on
knowledge/awareness of IPV and
company resources for IPV and number
of referrals for IPV assistance. This
extension is requested to cover the 12month follow-up administration of this
survey. Due to unexpected delays at the
evaluation site and an inability to field
the 6-month follow up survey with
managers when originally scheduled,
the project will need to be continued an
additional 3 months.
Employees (N = 400) of those
managers who completed the baseline
survey using an anonymous web-based
survey at baseline have been surveyed.
These employees will also be surveyed
12 months later (during the
reinstatement period) to assess their
self-evaluated productivity,
absenteeism, and perceptions of
manager behavior. Responses of
managers (and their employees) who
received the IPV training in the study
period (i.e., sometime between the
baseline and 12 month surveys) with
untrained managers will be compared.
The study will provide CDC and
employers information about the
potential effectiveness and costeffectiveness of workplace IPV
intervention strategies.
There are no costs to respondents
except their time to participate in the
interview.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of responses per
respondent
Number of
respondents
Respondents
Average
burden per
response (in
hours)
Total burden
(in hours)
Employee .........................................................................................................
Manager ...........................................................................................................
400
200
1
2
30/60
30/60
200
200
Total ..........................................................................................................
........................
........................
........................
400
Dated: August 19, 2009.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E9–20578 Filed 8–25–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Comment Request
jlentini on DSKJ8SOYB1PROD with NOTICES
Title: Grant Application Data
Summary (GADS) Form.
OMB No.: 0970–0328.
Description: The Grant Application
Data Summary (GADS) form collects
information from applicants seeking
grants from the Administration for
Native Americans (ANA). Applicants
complete the GADS form as part of their
funding package. This standardized
format allows ANA to evaluate
applications for financial assistance and
to determine the relative focus of the
projects for which such assistance is
requested. The data collected focuses on
the specific ANA program area for
which the applicant is applying. ANA
awards annual grants in the following
nine competitive areas: (1) Social &
Economic Develop Strategies (SEDS); (2)
Alaska SEDS; (3) Special Initiative:
Family Preservation: Improving the
Well-Being of Children Planning; (4)
Special Initiative: Family Preservation:
Improving the Well-Being of Children
Implementation; (5) Native Language
Preservation & Maintenance
Assessment; (6) Native Language
Preservation & Maintenance Planning;
(7) Native Language Preservation &
Maintenance Implementation; (8) Native
Language Preservation & Maintenance
Immersion; (9) Environmental
Regulatory Enhancement.
Respondents: Federally Recognized
Indian Tribes, Tribal Governments,
Native American Non-profits, Tribal
Colleges and Universities.
ANNUAL BURDEN ESTIMATES
Instrument
Number of
respondents
Number of responses per
respondent
Average burden hours per
response
Total burden
hours
Grant Application Data Summary (GADS) ......................................................
500
1
0.50
250
VerDate Nov<24>2008
17:05 Aug 25, 2009
Jkt 217001
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
E:\FR\FM\26AUN1.SGM
26AUN1
Agencies
[Federal Register Volume 74, Number 164 (Wednesday, August 26, 2009)]
[Notices]
[Pages 43138-43139]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-20578]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-09-0789]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-5960 or
send comments to Maryam I. Daneshvar, CDC Acting Reports Clearance
Officer, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail
to omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c)
[[Page 43139]]
ways to enhance the quality, utility, and clarity of the information to
be collected; and (d) ways to minimize the burden of the collection of
information on respondents, including through the use of automated
collection techniques or other forms of information technology. Written
comments should be received within 60 days of this notice.
Proposed Project
Program Effectiveness Evaluation of Workplace Intervention for
Intimate Partner Violence (IPV)--[OMB 0920-0789] [expiration
date 12/31/09]--Extension--National Center for Injury Prevention and
Control (NCIPC), Centers for Disease Control and Prevention (CDC).
Background and Brief Description
Intimate partner violence (IPV) affects a substantial number of
Americans, and there has recently been increasing recognition of the
impact it has on the workplace. In addition to direct impacts
(batterers often stalk or even attack IPV victims at their place of
work), IPV has indirect impacts on the workplace environment through
lost productivity due to medical leave, absenteeism, and fear and
distraction on the part of victims and coworkers. The Centers for
Disease Control and Prevention (CDC) contracted with RTI International
(RTI) to evaluate an ongoing workplace IPV prevention program being
implemented at a national corporation. The purpose of the proposed
evaluation is to document in detail the workplace IPV prevention
activities delivered by the company, to determine the impact of these
activities on short-term and long-term outcomes, and to determine the
cost-effectiveness of the program. All managers at the corporate office
of the corporation have been screened to assess training experiences.
More in-depth surveys were conducted with managers who had not
completed the corporation's IPV training. Approximately 200 managers
have been surveyed at baseline, and 6 months later. Manager surveys
focus on knowledge/awareness of IPV and company resources for IPV and
number of referrals for IPV assistance. This extension is requested to
cover the 12-month follow-up administration of this survey. Due to
unexpected delays at the evaluation site and an inability to field the
6-month follow up survey with managers when originally scheduled, the
project will need to be continued an additional 3 months.
Employees (N = 400) of those managers who completed the baseline
survey using an anonymous web-based survey at baseline have been
surveyed. These employees will also be surveyed 12 months later (during
the reinstatement period) to assess their self-evaluated productivity,
absenteeism, and perceptions of manager behavior. Responses of managers
(and their employees) who received the IPV training in the study period
(i.e., sometime between the baseline and 12 month surveys) with
untrained managers will be compared. The study will provide CDC and
employers information about the potential effectiveness and cost-
effectiveness of workplace IPV intervention strategies.
There are no costs to respondents except their time to participate
in the interview.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Respondents Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
Employee........................................ 400 1 30/60 200
Manager......................................... 200 2 30/60 200
---------------------------------------------------------------
Total....................................... .............. .............. .............. 400
----------------------------------------------------------------------------------------------------------------
Dated: August 19, 2009.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. E9-20578 Filed 8-25-09; 8:45 am]
BILLING CODE 4163-18-P